Investors might want to bet on MAIA Biotechnology, Inc. (MAIA), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

CHICAGO, April 01, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA" or the "Company"), a clinical-stage biopharmaceutical company ...

“MAIA continues to bring innovation to the biotech industry as one of the earliest pioneers of telomere targeting as a strategy for cancer treatment. Our lead candidate is THIO (ateganosine ...

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders ...

In this article, we are going to take a look at where MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) stands against other cheapest stocks insiders are buying in March. After solid gains Monday ...

MAIA Biotechnology, Inc. (MAIA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA – Free Report) – Diamond Equity raised their Q1 2025 EPS estimates for MAIA Biotechnology in a report issued on Tuesday, March 25th.

MAIA’s letter to shareholders is available at ir.maiabiotech.com. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Chicago-based Maia Biotechnology said this week that its lead drug candidate, THIO, has gained its generic name, and preclinical data on a different form of the cancer drug suggests it could ...